Robin P F Dullaart1, Wijtske Annema, Jan Freark de Boer, Uwe J F Tietge. 1. Department of Endocrinology, Center for Liver, Digestive and Metabolic Diseases, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands. r.p.f.dullaart@int.umcg.nl
Abstract
BACKGROUND: High density lipoproteins (HDLs) have been implicated in glucose homeostasis. Among subjects with normal fasting glucose (NFG), impaired fasting glucose (IFG) and Type 2 diabetes mellitus (T2DM) we tested whether pancreatic β-cell function relates to HDL functionality, as determined by HDL anti-oxidative capacity and cellular cholesterol efflux to plasma. SUBJECTS AND METHODS: HDL anti-oxidative capacity (inhibition of LDL oxidation in vitro), cellular cholesterol efflux (the ability of plasma to stimulate cholesterol efflux out of cultured fibroblasts obtained from a single human donor), glucose and insulin were determined in fasting plasma samples from 37 subjects with NFG, 36 with IFG and 22 with T2DM (no glucose lowering drug or insulin treatment; HbA1c 6.0±1.0%). Homeostasis model assessment was used to estimate pancreatic β-cell function (HOMA-β) and insulin resistance (HOMAir). RESULTS: HOMA-β was lowest, whereas HOMAir was highest in T2DM (P<0.01 and P<0.001 vs. NFG). HDL anti-oxidative capacity and cellular cholesterol efflux did not differ significantly according to glucose tolerance category. In univariate analysis and after controlling for HOMAir both HDL anti-oxidative capacity (P<0.05) and cellular cholesterol efflux (P<0.01) were positively correlated with HOMA-β in T2DM, but not in NFG and IFG. In age-, sex- and HOMAir-adjusted analyses, T2DM status interacted positively with HDL anti-oxidative capacity (P=0.001) and cellular cholesterol efflux (P=0.042) on HOMA-β. HbA1c interacted similarly with HDL functionality measures on HOMA-β. CONCLUSIONS: Pancreatic β-cell function relates to pathophysiologically relevant measures of HDL function in T2DM, but not in NFG and IFG. Better HDL functionality may contribute to maintenance of β-cell function in subjects with well-controlled T2DM.
BACKGROUND: High density lipoproteins (HDLs) have been implicated in glucose homeostasis. Among subjects with normal fasting glucose (NFG), impaired fasting glucose (IFG) and Type 2 diabetes mellitus (T2DM) we tested whether pancreatic β-cell function relates to HDL functionality, as determined by HDL anti-oxidative capacity and cellular cholesterol efflux to plasma. SUBJECTS AND METHODS: HDL anti-oxidative capacity (inhibition of LDL oxidation in vitro), cellular cholesterol efflux (the ability of plasma to stimulate cholesterol efflux out of cultured fibroblasts obtained from a single humandonor), glucose and insulin were determined in fasting plasma samples from 37 subjects with NFG, 36 with IFG and 22 with T2DM (no glucose lowering drug or insulin treatment; HbA1c 6.0±1.0%). Homeostasis model assessment was used to estimate pancreatic β-cell function (HOMA-β) and insulin resistance (HOMAir). RESULTS: HOMA-β was lowest, whereas HOMAir was highest in T2DM (P<0.01 and P<0.001 vs. NFG). HDL anti-oxidative capacity and cellular cholesterol efflux did not differ significantly according to glucose tolerance category. In univariate analysis and after controlling for HOMAir both HDL anti-oxidative capacity (P<0.05) and cellular cholesterol efflux (P<0.01) were positively correlated with HOMA-β in T2DM, but not in NFG and IFG. In age-, sex- and HOMAir-adjusted analyses, T2DM status interacted positively with HDL anti-oxidative capacity (P=0.001) and cellular cholesterol efflux (P=0.042) on HOMA-β. HbA1c interacted similarly with HDL functionality measures on HOMA-β. CONCLUSIONS:Pancreatic β-cell function relates to pathophysiologically relevant measures of HDL function in T2DM, but not in NFG and IFG. Better HDL functionality may contribute to maintenance of β-cell function in subjects with well-controlled T2DM.
Authors: Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Robin P F Dullaart; Jan-Stephan F Sanders; Stephan J L Bakker; Uwe J F Tietge Journal: J Am Soc Nephrol Date: 2015-08-28 Impact factor: 10.121
Authors: Preethi Mani; Hao-Yu Ren; Ian J Neeland; Darren K McGuire; Colby R Ayers; Amit Khera; Anand Rohatgi Journal: Diabetes Metab Syndr Date: 2016-12-12
Authors: Tatjana Josefs; Kristiaan Wouters; Uwe J F Tietge; Wijtske Annema; Robin P F Dullaart; Tomas Vaisar; Ilja C W Arts; Carla J H van der Kallen; Coen D A Stehouwer; Casper G Schalkwijk; Ira J Goldberg; Edward A Fisher; Marleen M J van Greevenbroek Journal: J Clin Lipidol Date: 2019-10-31 Impact factor: 4.766
Authors: Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Marleen M J van Greevenbroek; Carla J H van der Kallen; Casper G Schalkwijk; Coen D A Stehouwer; Robin P F Dullaart; Uwe J F Tietge Journal: Sci Rep Date: 2016-06-08 Impact factor: 4.379
Authors: Sara Sokooti; Jose L Flores-Guerrero; Lyanne M Kieneker; Hiddo J L Heerspink; Margery A Connelly; Stephan J L Bakker; Robin P F Dullaart Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Johanna Apro; Uwe J F Tietge; Arne Dikkers; Paolo Parini; Bo Angelin; Mats Rudling Journal: Arterioscler Thromb Vasc Biol Date: 2016-03-31 Impact factor: 8.311